Is Osterro (bone-supporting supplement) indicated for the treatment of tardive dyskinesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Osterro is NOT indicated for tardive dyskinesia treatment

Osterro (treprostinil) is FDA-approved exclusively for pulmonary arterial hypertension (PAH), not tardive dyskinesia. The drug label evidence clearly demonstrates this medication is a prostacyclin analog used to treat PAH by improving exercise capacity and delaying clinical worsening 111. There is no mention of tardive dyskinesia in any of the FDA labeling materials.

The Correct Treatment for Tardive Dyskinesia

For moderate to severe or disabling tardive dyskinesia, the American Psychiatric Association strongly recommends (1B) treatment with a VMAT2 inhibitor 2. This is the highest-level recommendation in the APA guidelines for TD pharmacotherapy.

VMAT2 Inhibitors: First-Line Treatment

The FDA-approved VMAT2 inhibitors for TD are:

  • Valbenazine - demonstrated moderate-quality evidence of benefit (RR 0.63,95% CI 0.46 to 0.86) 3
  • Deutetrabenazine - approved in 2017 with demonstrated efficacy in class 1 studies 4

These agents work by reducing dopamine signaling dysregulation without directly blocking D2 receptors, effectively managing symptoms while avoiding the mechanism that causes TD 5.

Treatment Algorithm

  1. First step: Optimize the antipsychotic regimen - consider dose reduction or switching to a lower-risk agent before adding TD-specific treatment 65

  2. For moderate-to-severe TD: Initiate VMAT2 inhibitor therapy (valbenazine or deutetrabenazine) 25

  3. Monitor carefully: Use validated scales like the Abnormal Involuntary Movement Scale (AIMS) to track response 5

Alternative Agents (Lower Evidence Quality)

If VMAT2 inhibitors are unavailable or contraindicated, very low-quality evidence suggests potential benefit from:

  • Ginkgo biloba extract (RR 0.88,95% CI 0.81 to 0.96) 3
  • Vitamin E (SMD = -1.18) 7

However, these should only be considered within research contexts given the limited evidence 3.

Critical Caveat

Serious adverse events with VMAT2 inhibitors include psychiatric symptoms (depression, worsening schizophrenia, suicidal ideation) 7. Close psychiatric monitoring is essential when initiating these medications, particularly in patients with underlying psychiatric disorders.

The confusion about "Osterro" likely stems from similarity in naming, but this PAH medication has no role in movement disorder management.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.